Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Disease-Free Survival
Fallopian Tube Neoplasms
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Peritoneal Neoplasms
Piperidines
Quinazolines
Taxoids
Treatment Outcome

authors with profiles

WEI HU
ANIL K SOOD
ROBERT COLEMAN